Patents by Inventor Robert Johan Joseph Hageman

Robert Johan Joseph Hageman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10821120
    Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 3, 2020
    Assignee: N.V. Nutricia
    Inventors: Sofia Lopes Da Silva, Ladislaus Maria Broersen, Robert Johan Joseph Hageman, Jan Maarten Verkuijl
  • Publication number: 20200261488
    Abstract: The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the subject a composition comprising therapeutically effective amounts of: (i) one or more of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), preferably at least DHA, more preferably DHA and EPA, wherein the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.
    Type: Application
    Filed: January 10, 2020
    Publication date: August 20, 2020
    Inventors: Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman
  • Patent number: 10675292
    Abstract: The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: June 9, 2020
    Assignee: N.V. NUTRICIA
    Inventors: Nick Van Wijk, Robert Johan Joseph Hageman, Mehmet Cansev
  • Publication number: 20200146326
    Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Robert Johan Joseph Hageman, Ladislaus Maria Broersen, Nick Van Wijk
  • Patent number: 10449248
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter; (b) at least 12 wt % of leucine, based on total proteinaceous matter; (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) an immune modulator; for improving the immune function in a mammal, preferably a human.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: October 22, 2019
    Assignee: N. V. Nutricia
    Inventors: Joyce Faber, Adrianus Lambertus Bertholdus Van Helvoort, Klaske Van Norren, Arjan Paul Vos, Robert Johan Joseph Hageman, Cornelus Johannes Petrus Van Limpt
  • Publication number: 20190183916
    Abstract: The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.
    Type: Application
    Filed: August 23, 2017
    Publication date: June 20, 2019
    Applicant: N.V. Nutricia
    Inventor: Robert Johan Joseph HAGEMAN
  • Publication number: 20190175622
    Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.
    Type: Application
    Filed: June 9, 2017
    Publication date: June 13, 2019
    Applicant: N.V. NUTRICIA
    Inventors: Sofia LOPES DA SILVA, Ladislaus Maria BROERSEN, Robert Johan Joseph HAGEMAN, Jan Maarten VERKUIJL
  • Publication number: 20180311196
    Abstract: The invention pertains to the use of a composition in the manufacture of a productor method for therapeutically improving, promoting, restoring or maintaining white matter integrity in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired white matter integrity associated with PKU, said composition comprising therapeutic amounts of at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); and one of more of uridine, cytidine and/or an equivalent thereof, including salts, phosphates, acyl derivatives and/or esters. The invention also pertains to a composition for use in such use or method.
    Type: Application
    Filed: October 24, 2016
    Publication date: November 1, 2018
    Applicant: N.V. Nutricia
    Inventors: Paul Johannes Maria SAVELKOUL, Jan Maarten VERKUIJL, Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE, Danielle Stefanie COUNOTTE, Maryam RAKHSHANDEHROO
  • Patent number: 10071072
    Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 11, 2018
    Assignee: N.V. NUTRICIA
    Inventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Sijben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
  • Patent number: 9968629
    Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 ?M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: May 15, 2018
    Assignee: N.V. Nutricia
    Inventors: Martine Groenendijk, Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde
  • Patent number: 9950013
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 24, 2018
    Assignee: N. V. Nutricia
    Inventors: Klaske Van Norren, Adrianus Lambertus Bertholdus Van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos
  • Patent number: 9889149
    Abstract: The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 13, 2018
    Assignee: N.V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Patent number: 9867796
    Abstract: The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 16, 2018
    Assignee: N.V. Nutricia
    Inventors: Klaske Van Norren, Joyce Faber, Adrianus Lambertus Bertholdus Van Helvoort, Robert Johan Joseph Hageman
  • Patent number: 9844525
    Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B 12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 19, 2017
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Patent number: 9795628
    Abstract: The invention relates to a nutritional composition comprising dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behavior. The invention further relates to a combination of dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behavior.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 24, 2017
    Assignee: N.V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Publication number: 20170157164
    Abstract: The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.
    Type: Application
    Filed: February 2, 2015
    Publication date: June 8, 2017
    Applicant: N.V. Nutricia
    Inventors: Nick VAN WIJK, Robert Johan Joseph HAGEMAN, Mehmet CANSEV
  • Publication number: 20170157163
    Abstract: The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof in the manufacture of a composition for use in a method for treating, stabilizing or slowing down brain glucose metabolism deficit in a subject in need thereof.
    Type: Application
    Filed: February 2, 2015
    Publication date: June 8, 2017
    Applicant: N.V. Nutricia
    Inventors: Maria Ladislaus BROERSEN, Robert Johan Joseph HAGEMAN, Marieke LANSBERGEN, Martine GROENENDIJK, Mattheus Cornelis DE WILDE
  • Publication number: 20170157177
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 8, 2017
    Inventors: Klaske Van Norren, Adrianus Lambertus Bertholdus Van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos
  • Publication number: 20170135975
    Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Applicant: N.V. Nutricia
    Inventors: Mattheus Cornelis DE WILDE, Johannes Wilhelmus Christina SIJBEN, Patrick Joseph Gerardus Hendrikus KAMPHUIS, Robert Johan Joseph HAGEMAN
  • Patent number: 9642390
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 9, 2017
    Assignee: N.V. Nutricia
    Inventors: Klaske van Norren, Adrianus Lambertus Bertholdus van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos